Evidence map›Paper›PMID 30570809›Full record

ArticleJournal of thrombosis and haemostasis : JTH2019

A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study.

Annatina Schnegg-Kaufmann, Sara Calzavarini, Andreas Limacher, Marie Mean, Marc Righini, Daniel Staub, Juerg-Hans Beer, Beat Frauchiger, Joseph Osterwalder, Nils Kucher and 11 more

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Thrombophilia and outcomes of venous thromboembolism in older patients.Research and practice in thrombosis and haemostasis · 2023
    Article
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Annatina Schnegg-KaufmannDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Sara CalzavariniDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Andreas LimacherCTU Bern, and Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.
Marie MeanDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Marc RighiniDivision of Angiology and Hemostasis, Geneva University Hospital, Geneva, Switzerland.
Daniel StaubDivision of Angiology, Basel University Hospital, Basel, Switzerland.
Juerg-Hans BeerDepartment of Internal Medicine, Cantonal Hospital of Baden, Baden, Switzerland.
Beat FrauchigerDepartment of Internal Medicine, Cantonal Hospital of Frauenfeld, Frauenfeld, Switzerland.
Joseph OsterwalderCantonal Hospital of St Gallen, Gallen, Switzerland.
Nils KucherUniversity Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland.
Christian M MatterCenter for Molecular Cardiology, University of Zurich, and Clinic for Cardiology, University Heart Center, Zurich University Hospital, Zurich, Switzerland.
Marc HusmannUniversity Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland.
Martin BanyaiDivision of Angiology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
Markus AschwandenDivision of Angiology, Basel University Hospital, Basel, Switzerland.
Lucia MazzolaiService of Angiology, Lausanne University Hospital, Lausanne, Switzerland.
Oliver HugliEmergency Department, Lausanne University Hospital, Lausanne, Switzerland.
Michael NaglerDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0003-4319-2367
Michael DaskalakisDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Nicolas RodondiDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Drahomir AujeskyDepartment of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Anne Angelillo-ScherrerDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID 0000-0003-2872-4863
University of Bern · CHUniversity Hospital of Basel · CHUniversity Hospital of Zurich · CHUniversity of Lausanne · CHKantonsspital Baden · CHKantonsspital Frauenfeld · CHKantonsspital St. Gallen · CHUniversity Hospital of Geneva · CHUniversity of Lucerne · CHUniversity of Zurich · CH

Funding

Swiss National Science Foundation 310030_153436Swiss National Science Foundation 314730_173127Swiss National Science Foundation 33CSCO-122659/139 470
6 · The paper itself

Abstract

Essentials Predictive ability of pro-hemostatic Gas6 for recurrent venous thromboembolism (VTE) is unknown. We measured Gas6 levels in 864 patients with VTE over 3 years. High Gas6 (> 157%) at diagnosis is associated with VTE recurrence, major bleeding and mortality. Gas6 plasma levels measured 12 months after the index VTE are discriminatory for VTE recurrence. SUMMARY: Background Growth arrest-specific gene 6 (Gas6) is a prohemostatic protein with an unknown predictive ability for recurrent venous thromboembolism (VTE). In the elderly, VTE results in higher mortality but does not have a higher rate of recurrence than in younger patients. Consequently, anticoagulation management in the elderly is challenging. Objective To prospectively investigate the performance of Gas6 in predicting VTE recurrence, major bleeding and mortality in the elderly. Methods Consecutive patients aged ≥ 65 years with acute VTE were followed for a period of 3 years. Primary outcomes were symptomatic VTE recurrence, major bleeding, and mortality. Plasma Gas6 was measured with ELISA. Results Gas6 levels were measured in 864 patients at the time of the index VTE (T1) and, in 70% of them, also 12 months later (T2). The Gas6 level at T1 was discriminatory for VTE recurrence (C-statistic, 0.56; 95% confidence interval [CI] 0.51-0.62), major bleeding (0.60, 95% CI 0.55-0.65) and mortality (0.69, 95% CI 0.65-0.73) up to 36 months. VTE recurrence up to 24 months after T2 was discriminated by the Gas6 level at T2 (0.62, 95% CI 0.54-0.71). High Gas6 levels (> 157%) and continuous Gas6 levels at T1 were associated with VTE recurrence up to 6 months and 12 months, respectively. Conclusions In elderly patients, a high Gas6 level is associated with higher risks of VTE recurrence, major bleeding, and death. These findings support further studies to assess the performance of Gas6 in adjusting the length of anticoagulation.

Indexed as

AgedAged, 80 and overAge FactorsAnticoagulantsBiomarkersFemaleGrowth Arrest-Specific Protein 6HemorrhageHumansIncidenceIntercellular Signaling Peptides and ProteinsMaleProspective StudiesRecurrenceRisk AssessmentRisk FactorsAnticoagulantsBiomarkersGrowth Arrest-Specific Protein 6Intercellular Signaling Peptides and Proteinsagedcohort studiesgrowth arrest-specific gene 6mortalityvenous thromboembolism

Identifiers

PMID30570809
PMCPMC6850608
OpenAlexW2911953428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.